Stage 2 is characterised by glucose intolerance or dysglycaemia, while stage 3 T1DM is characterised by the biochemical criteria for diabetes in asymptomatic (stage 3a) or symptomatic people (stage 3b) who will require insulin therapy [18]. This evidence concerns the gene INS and diabetes mellitus.